Zydus Lifesciences

Zydus Lifesciences

has entered into a licensing and supply agreement with Lupin to expand access to its

已与Lupin达成许可和供应协议，以扩大对其产品的获取途径

generic version of semaglutide

通用版本的司美鲁肽

that will be launched soon in the Indian market.

这将很快在印度市场推出。

The patent for Danish drugmaker Novo Nordisk’s innovative weight-loss and diabetes molecule

丹麦制药公司诺和诺德的创新减肥和糖尿病分子专利

semaglutide

司美格鲁肽

– sold in India under the brand names Wegovy and Ozempic – will expire on March 21. Several leading Indian drugmakers have lined up generic launches immediately after the patent expires.

——在印度以Wegovy和Ozempic品牌销售——将于3月21日到期。几家印度主要制药商已准备在专利到期后立即推出仿制药。

Also Read:

另请阅读：

Weight-loss drug boom: Will cheaper Ozempic generics shake up India’s fitness and nutrition industry?

减肥药热潮：更便宜的Ozempic仿制药会撼动印度的健身与营养行业吗？

The partnership is for Zydus’s semaglutide injection (15 mg/3 ml) with reusable pen device and is aimed at leveraging Lupin’s reach in the Indian market, Ahmedabad-based Zydus said in a statement.

Zydus在一份声明中表示，此次合作涉及Zydus的司美鲁肽注射液（15毫克/3毫升）及可重复使用的笔式装置，旨在利用Lupin在印度市场的覆盖范围。

Sharvil Patel, Managing Director, Zydus Lifesciences, said: “The innovative pen device we are offering is designed to make therapy simpler and improve quality of life.” He added that the collaboration with Lupin will help broaden access to the medicine, thereby expand its reach.

Zydus Lifesciences董事总经理Sharvil Patel表示：“我们提供的创新型笔式装置旨在使治疗更简单，并提高生活质量。”他补充说，与Lupin的合作将有助于扩大药品的可及性，从而拓展其覆盖范围。

Live Events

现场活动

Under this agreement, Lupin will have semi-exclusive rights to co-market Zydus’ semaglutide injection in the Indian market under the brand names Semanext and Lupin’s Livarise.

根据该协议，Lupin将拥有在印度市场以品牌名Semanext和Lupin的Livarise共同销售Zydus的司美鲁肽注射剂的半独家权利。

Also Read:

另请阅读：

Mankind Pharma targets early Semaglutide launch

人类制药公司目标提早推出司美鲁肽

Zydus will market the product under the brand names Semaglyntm, Mashematm and Altermetm. Lupin will pay Zydus upfront licensing fees and milestone payments on achieving pre-defined milestones.

Zydus 将以 Semaglyntm、Mashematm 和 Altermetm 品牌销售该产品。Lupin 将向 Zydus 支付预付许可费，并在达成预定义的里程碑时支付里程碑款项。

Nilesh Gupta, Managing Director, Lupin, said: 'As GLP 1 therapies continue to redefine treatment standards globally, this collaboration enhances our diabetes portfolio and reinforces our focus on addressing unmet patient needs.”

鲁宾公司的总经理尼莱什·古普塔表示：“随着GLP-1疗法继续重新定义全球治疗标准，此次合作增强了我们的糖尿病产品组合，并加强了我们对解决未满足患者需求的关注。”

Add

添加

as a Reliable and Trusted News Source

作为可靠和值得信赖的新闻来源

Add Now!

立即添加！

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)

(You can now subscribe to our

（你现在可以订阅我们的

Economic Times WhatsApp channel

经济时报WhatsApp频道

)

)